Featured Research

from universities, journals, and other organizations

Ovarian Cancer Drug Trial Reveals Promising New Treatment

Date:
September 15, 2008
Source:
University of California - Irvine
Summary:
Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.

Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease.

Dr. Bradley Monk, a UC Irvine gynecologic oncologist who led the worldwide phase III clinical trial, said trabectedin is the most recent addition to a short list of active drug therapies for recurrent ovarian cancer. He presents study results Sept. 15 at the 33rd Congress of the European Society for Medical Oncology in Stockholm.

"These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," said Monk, an associate professor who studies and treats ovarian cancers at the Chao Family Comprehensive Cancer Center at UC Irvine. "This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much needed option."

Phase III studies are multicenter trials on large patient groups designed to be the definitive assessment of a drug's effectiveness. Such a study is often the last step before a drug is reviewed by a regulatory agency like the FDA for approval as a safe, effective treatment.

In this trial, an international group of researchers treated 672 women whose ovarian cancer had progressed after first-line treatment. Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin. The other half received the chemotherapy drug alone, which is standard treatment in these cases.

In patients on the combination therapy, researchers found no progression of the cancer for an average of 7.3 months, as compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free time was 9.2 months for the combination treatment, as compared to 7.5 months for the other patients.

Under the brand name Yondelis, trabectedin is approved in Europe and South Korea for treating advanced soft tissue sarcoma. In addition to the phase III ovarian cancer trial, it is being studied in smaller, phase II trials for prostate, breast and pediatric cancers.

Trabectedin is a synthetic version of a compound isolated from the sea squirt, a tubular sea animal used in a number of medical studies. It binds to the DNA of a cancer cell and blocks its ability to multiply, thus killing the cells and shrinking tumors.

When ovarian cancer is detected early – when it is confined to the ovaries – more than 90 percent of women will live at least five years, according to the American Cancer Society. Only about 20 percent of cases are detected that early. If the cancer is detected after it has spread, only about 30 percent of women survive five years. Each year, approximately 20,000 American women are diagnosed with ovarian cancer and about 15,000 die of the disease.

About the Chao Family Comprehensive Cancer Center: UC Irvine Healthcare's Chao Family Comprehensive Cancer Center provides fully integrated research, prevention, diagnostic, treatment and rehabilitation programs for patients and families coping with cancer. The cancer center is one of 41 National Cancer Institute-designated Comprehensive Cancer Centers nationwide and the only one in Orange County. The designation is the highest honor given by the NCI in recognition for excellence in cancer research and treatment.


Story Source:

The above story is based on materials provided by University of California - Irvine. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Irvine. "Ovarian Cancer Drug Trial Reveals Promising New Treatment." ScienceDaily. ScienceDaily, 15 September 2008. <www.sciencedaily.com/releases/2008/09/080915083351.htm>.
University of California - Irvine. (2008, September 15). Ovarian Cancer Drug Trial Reveals Promising New Treatment. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2008/09/080915083351.htm
University of California - Irvine. "Ovarian Cancer Drug Trial Reveals Promising New Treatment." ScienceDaily. www.sciencedaily.com/releases/2008/09/080915083351.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins